Effects of panobinostat: A Synthesis of Findings from 24 Studies

  1. Home
  2. Effects of panobinostat
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of panobinostat: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of panobinostat: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Panobinostat, a histone deacetylase inhibitor, has demonstrated effectiveness in inhibiting cancer cell growth and inducing apoptosis in a variety of cancer types. 5 , 16 , 11 , 4 , 22 , 23 , 19 , 10 , 2 , 7 , 12 , 3 Panobinostat has also shown promise in combination therapies with other anticancer drugs. For example, panobinostat combined with DNA damaging agents like cisplatin, doxorubicin, and etoposide enhanced their antitumor activity in neuroblastoma. 18 Additionally, panobinostat, when combined with mTOR inhibitors such as rapamycin, showed improved efficacy against triple-negative breast cancer. 23 Furthermore, panobinostat has demonstrated synergistic effects with chemotherapy drugs like 5-fluorouracil in suppressing gastric cancer growth. 12

Benefits and Risks

Benefit Summary

Panobinostat has shown promising results in inhibiting cancer cell growth and inducing apoptosis across various cancer types. Its potential to enhance the effectiveness of other anticancer drugs through combination therapy further supports its role in cancer treatment.

Risk Summary

Panobinostat can cause certain side effects, including nausea, vomiting, diarrhea, fatigue, and rash. It may also affect the liver and kidneys. The risk of side effects can vary depending on factors like age, health condition, and other medications being taken. It is crucial to consult with a doctor regarding the potential risks associated with panobinostat.

Comparison Between Studies

Similarities

All studies consistently demonstrate the effectiveness of panobinostat in inhibiting cancer cell growth and inducing apoptosis. Additionally, the studies agree on panobinostat's potential to enhance the efficacy of other anticancer drugs when used in combination therapy.

Differences

The studies differ in the types of cancer investigated, the administration methods of panobinostat, and the specific combinations used with other anticancer drugs. For instance, 5 focuses on mouse mammary carcinoma, 16 examines human acute lymphoblastic leukemia cells, and 18 investigates neuroblastoma cells. The delivery method of panobinostat also varies; 22 uses liposome encapsulation for drug delivery. The combinations with other anticancer drugs are not uniform, as illustrated by 18 , which employs combinations with DNA damaging agents. These variations highlight the need for further research to fully understand the effectiveness and potential side effects of panobinostat in different contexts.

Consistency and Inconsistencies

The research results consistently indicate that panobinostat effectively inhibits cancer cell growth and induces apoptosis. However, variations exist in the observed effectiveness and side effects. For example, 3 notes the potential of panobinostat to affect the liver and kidneys. These inconsistencies emphasize the need for further investigation to gain a comprehensive understanding of panobinostat's effects.

Implications for Everyday Life

While panobinostat holds significant promise as a cancer treatment, it is still in the clinical trial phase. Its widespread availability may take some time. Moreover, the possibility of side effects should be considered. It is crucial to consult with a doctor before using panobinostat.

Limitations of Current Research

The current studies are limited by the specific cancer types and patient populations investigated. To gain a more general understanding of panobinostat's effectiveness and side effects, further research with a broader range of cancers and patients is necessary.

Future Research Directions

Future research should focus on expanding clinical trials to include a wider variety of cancers and patients, aiming for a more comprehensive understanding of panobinostat's effectiveness and side effects. Optimizing the administration methods of panobinostat and exploring the best combination therapies with other anticancer drugs are crucial areas for future research.

Conclusion

Panobinostat is a histone deacetylase inhibitor that has shown promising results in inhibiting cancer cell growth and inducing apoptosis across various cancer types. Its potential to enhance the effectiveness of other anticancer drugs through combination therapy further supports its role in cancer treatment. However, further research is necessary to fully understand its effectiveness and potential side effects. It is crucial to consult with a doctor before using panobinostat.

Literature analysis of 24 papers
Positive Content
24
Neutral Content
0
Negative Content
0
Article Type
0
1
0
1
24
1.

Natural compound library screening identifies Sanguinarine chloride for the treatment of SCLC by upregulating CDKN1A.

Author: ZhongMingtian, LiXun, ZhaoFengyun, HuangYanni, LongYihao, ChenKaizhao, TianXuemei, LiuMing, MaXiaodong

SCLC treatment

Sanguinarine chloride was found to be a potential inhibitor of small cell lung cancer (SCLC) by upregulating the expression of CDKN1A. This compound, when combined with chemotherapy drugs, showed strong synergistic anti-SCLC properties.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway.

Author: ShengBo, WangWenwen, XiaDongyue, QuXiangdong

Cervical cancer treatment

Combining LBH589 and AM1241 synergistically induced apoptosis in cervical cancer cells. This combination activated the endoplasmic reticulum emergency pathway, DNA damage repair signaling pathway, oxidative stress, and autophagy pathway, ultimately promoting apoptosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines.

Author: PachecoMariana Brütt, CamiloVânia, LopesNair, Moreira-SilvaFilipa, CorreiaMargareta P, HenriqueRui, JerónimoCarmen

Prostate cancer treatment

This study investigates the use of epigenetic drugs, including hydralazine, panobinostat, and valproic acid, to treat prostate cancer. The study found that these drugs were effective in inhibiting the growth of prostate cancer cells in laboratory settings.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.

Author: SearsThomas K, HorbinskiCraig M, WoolardKevin D

HDAC inhibitor
IDH1/2 mutation
glioma treatment

IDH1/2 mutations lead to increased DNA and histone methylation, which may make IDH1/2 mutated gliomas more sensitive to HDAC inhibitors due to increased HDAC activity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.

Author: KlingMatthew J, KesherwaniVarun, MishraNitish K, AlexanderGracey, McIntyreErin M, RaySutapa, ChallagundlaKishore B, JoshiShantaram S, CoulterDon W, ChaturvediNagendra K

Medulloblastoma treatment

Medulloblastoma (MB) is a brain tumor with poor outcomes in patients with MYC oncogene amplification or overexpression. This study explored the therapeutic potential of inhibiting BET proteins and HDACs together in MB.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time.

Author: BilbaoMichelle, KatzChelsea, KassStephanie L, SmithDevon, HunterKrystal, WarshalDavid, AikinsJames K, OstrovskyOlga

Epigenetic therapy efficacy
Cancer cell repopulation

In a 3D spheroid model of recurrent high-grade serous ovarian cancer, panobinostat, an epigenetic therapy, effectively reversed the exponential growth induced by paclitaxel, a classic chemotherapy drug. This finding highlights the potential of epigenetic therapy in overcoming chemotherapy resistance in recurrent ovarian cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Panobinostat-loaded folate targeted liposomes as a promising drug delivery system for treatment of canine B-cell lymphoma.

Author: AndréAna S, DiasJoana N R, AguiarSandra I, LeonardoAna, NogueiraSara, AmaralJoana D, FernandesCélia, GanoLurdes, CorreiaJoão D G, CavacoMarco, NevesVera, CorreiaJorge, CastanhoMiguel, RodriguesCecília M P, GasparMaria Manuela, TavaresLuís, Aires-da-SilvaFrederico

Potential treatment for canine B-cell lymphoma

This study investigated the potential of panobinostat (Pan)-loaded folate-targeted PEGylated liposomes (FA-PEG-Pan-Lip) for the treatment of canine B-cell lymphoma, highlighting the potential for comparative oncology research to accelerate therapeutic development for both humans and animals.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease.

Author: DingHaodong, LiYuwei, FangMaoxin, ChenJiaojiao, LiuLipin, LuZhigang, HouJia, LuoMin

X-linked MAGT1 deficiency is a rare immunodeficiency characterized by increased susceptibility to Epstein-Barr virus (EBV) infection and defective N-linked glycosylation. This study explores the similarity between MAGT1 and TUSC3, two genes with shared functions. The findings suggest that TUSC3 may play a role in EBV-associated malignancies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia.

Author: JiangChuang, QianMaoxiang, GochoYoshihiro, YangWentao, DuGuoqing, ShenShuhong, YangJun J, ZhangHui

Antileukemia effects
Drug resistance

Mitochondrial activity was identified as the driver of panobinostat resistance in acute lymphoblastic leukemia (ALL). Ectopic SIRT1 expression activated mitochondrial activity and sensitized ALL to panobinostat, suggesting a potential role for SIRT1 as a biomarker of panobinostat response in cancers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.

Author: EkeIris, AryankalayilMolykutty J, BylickyMichelle A, MakindeAdeola Y, LiottaLance, CalvertValerie, PetricoinEmanuel F, GravesEdward E, ColemanC Norman

Prostate cancer treatment

Understanding the molecular changes after irradiation can aid in optimizing the efficacy of multimodal radiation oncology in combination with post-irradiation molecularly-targeted drug treatment. Cells which survived a single dose of 10 Gy irradiation showed a long-term upregulation and increased activity of multiple molecular targets including AKT, IGF-1R, VEGFR2, or MET.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.

Language : English

19.

Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.

Author: SalmonJessica M, TodorovskiIzabela, StanleyKym L, BruedigamClaudia, KearneyConor J, MartelottoLuciano G, RosselloFernando, SempleTimothy, ArnauGisela Mir, ZethovenMagnus, BotsMichael, BjelosevicStefan, CluseLeonie A, FraserPeter J, LitalienVeronique, VidacsEva, McArthurKate, MatthewsAntony Y, GressierElise, de WeerdNicole A, LichteJens, KellyMadison J, HoggSimon J, HertzogPaul J, KatsLev M, VervoortStephin J, De CarvalhoDaniel D, ScheuStefanie, BedouiSammy, KileBenjamin T, LaneSteven W, PerkinsAndrew C, WeiAndrew H, DominguezPilar M, JohnstoneRicky W

AML treatment
Antitumor immunity

This study discovered a novel immunoregulatory mechanism through inhibition of histone deacetylases (HDAC) in acute myeloid leukemia (AML). The study found that the HDAC inhibitor (HDACi) panobinostat induced type I interferon (IFN) signaling in leukemia cells, which was essential for leukemia cell differentiation and therapeutic benefit.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.

Author: ChenHaimin, ChenHaiqi, ZhouYan, XuWeiwei, YuJingjing, XuYao, ZhouFan

RRMM treatment

This network meta-analysis compares the effectiveness of different novel drug combinations for treating relapsed and/or refractory multiple myeloma (RRMM). Multiple myeloma is a type of blood cancer, and new treatment options have emerged for managing the disease.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Chemotherapy in pediatric brain tumor and the challenge of the blood-brain barrier.

Author: MalikJohid Reza, PodanyAnthony T, KhanParvez, ShafferChristopher L, SiddiquiJawed A, Baranowska-KortylewiczJanina, LeJennifer, FletcherCourtney V, EtherSadia Afruz, AvedissianSean N

Improved PBT treatment
Radiation therapy side effects

Pediatric brain tumors are a leading cause of cancer deaths in children. While chemoradiation has improved survival, it also has long-term side effects. There is a need for new chemotherapy drugs to avoid the need for radiation therapy. The blood-brain barrier is a major obstacle for drug delivery to the brain. More research is needed to understand how to get drugs into the brain to treat these tumors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer.

Author: WuKunlin, ZhangHuihao, ZhouLinlin, ChenLing, MoCaiqin, XuSunwang, LinJunyu, KongLingjun, ChenXiangjin

PANO/RAPA combination
TNBC treatment

A combination of panobinostat, a histone deacetylase inhibitor, and rapamycin, an mTOR inhibitor, shows promising anticancer effects against triple-negative breast cancer (TNBC) in both cell culture and mouse models. The combination was more effective than monotherapy in reducing tumor growth and inducing apoptosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.